The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease

Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia. It can linger for many years, but ultimately is fatal, the 6th leading cause of death. Alzheimer's disease (AD) is fatal and affected individuals can sometimes linger many years. Current treatments are palliative and transient, not disease modifying. This article reviews progress in the search to identify the primary AD-causing toxins. We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Aβ oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X. These findings have established the oligomer hypothesis as a new molecular basis for the cause, diagnosis, and treatment of AD.

[1]  D. Selkoe Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. , 1989, Cell.

[2]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[3]  F. Gage,et al.  Neural consequences of enviromental enrichment , 2000, Nature Reviews Neuroscience.

[4]  K. Blennow,et al.  Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease , 2010, PloS one.

[5]  E. Bigio,et al.  Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.

[6]  P. Siekevitz The postsynaptic density : A possible role in long-lasting effects in the central nervous system ( theory / protein modifications / structure change / synaptic strength ) , 2022 .

[7]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[8]  R. Anwyl,et al.  Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 , 2004, The Journal of Neuroscience.

[9]  A. Jasiński,et al.  Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. , 2010, Acta neurochirurgica. Supplement.

[10]  Jill A. White,et al.  Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation , 2005, Neurobiology of Disease.

[11]  Seiji Nishino,et al.  Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.

[12]  S. M. de la Monte,et al.  Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. , 2008, Journal of Alzheimer's disease : JAD.

[13]  P. Riederer,et al.  Diabetes Type II: A Risk Factor for Depression–Parkinson–Alzheimer? , 2011, Neurotoxicity Research.

[14]  R. Martins,et al.  Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.

[15]  M. White Insulin Signaling in Health and Disease , 2003, Science.

[16]  P. Greengard,et al.  Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses , 2005, Neurobiology of Disease.

[17]  C. Heizmann,et al.  Site-Specific Blockade of RAGE-Vd Prevents Amyloid-β Oligomer Neurotoxicity , 2008, The Journal of Neuroscience.

[18]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[19]  Shaomin Li,et al.  Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.

[20]  R. Malinow,et al.  AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss , 2006, Neuron.

[21]  S. Hoyer Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism. , 1998, Journal of neural transmission. Supplementum.

[22]  P. Riederer,et al.  Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. , 2010, Journal of Alzheimer's disease : JAD.

[23]  M. Sheng,et al.  PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.

[24]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[25]  O. Arancio,et al.  Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. , 2010, Journal of visualized experiments : JoVE.

[26]  D. Selkoe The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. , 2000, Neurologic clinics.

[27]  N. Chauhan Intracerebroventricular passive immunization with anti‐oligoAβ antibody in TgCRND8 , 2007, Journal of neuroscience research.

[28]  R. Hepler,et al.  Solution State Characterization of Amyloid β-Derived Diffusible Ligands , 2006 .

[29]  E. Cavalheiro,et al.  Activation of D1/D5 Dopamine Receptors Protects Neurons from Synapse Dysfunction Induced by Amyloid-β Oligomers* , 2010, The Journal of Biological Chemistry.

[30]  Peter Schönknecht,et al.  Type II diabetes in mild cognitive impairment and Alzheimer's disease: results from a prospective population-based study in Germany. , 2009, Journal of Alzheimer's disease : JAD.

[31]  A. Aguzzi,et al.  Supplementary figure legends , 2010 .

[32]  D. Price,et al.  Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Tao Wang,et al.  Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model , 2010, Molecular Neurodegeneration.

[34]  M. Kennedy,et al.  Signal-processing machines at the postsynaptic density. , 2000, Science.

[35]  W. Klein,et al.  Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.

[36]  C. Finch,et al.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  R. Balázs,et al.  β-Amyloid-(1–42) Impairs Activity-dependent cAMP-response Element-binding Protein Signaling in Neurons at Concentrations in Which Cell Survival Is Not Compromised* , 2001, The Journal of Biological Chemistry.

[38]  E. Ziff Enlightening the Postsynaptic Density , 1997, Neuron.

[39]  Ian Parker,et al.  Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.

[40]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  N. Inestrosa,et al.  Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses , 2010, Proceedings of the National Academy of Sciences.

[42]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[43]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[44]  Inflammation in Alzheimer’s Disease , 2001 .

[45]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[46]  C. Bramham Local protein synthesis, actin dynamics, and LTP consolidation , 2008, Current Opinion in Neurobiology.

[47]  L. Reagan,et al.  Insulin signaling effects on memory and mood. , 2007, Current opinion in pharmacology.

[48]  J. Deussing,et al.  Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices , 2011, Neuropharmacology.

[49]  Ling Li,et al.  Intake of Sucrose-sweetened Water Induces Insulin Resistance and Exacerbates Memory Deficits and Amyloidosis in a Transgenic Mouse Model of Alzheimer Disease* , 2007, Journal of Biological Chemistry.

[50]  松崎 尊信 Insulin resistance is associated with the pathology of Alzheimer's disease : the Hisayama study , 2010 .

[51]  Steven A. Johnson,et al.  Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress , 1995, Experimental Neurology.

[52]  W. Klein,et al.  The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. , 2009, The American journal of pathology.

[53]  B. Kriem,et al.  Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. , 2006, The Journal of biological chemistry.

[54]  P. Keller,et al.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.

[55]  S. Woods,et al.  Intracerebroventricular insulin enhances memory in a passive-avoidance task , 2000, Physiology & Behavior.

[56]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[57]  J. Malter,et al.  FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein , 2007, PLoS biology.

[58]  A. Scheibel,et al.  Progressive dendritic changes in aging human cortex , 1975, Experimental Neurology.

[59]  Y. Sheline,et al.  Memory improvement following induced hyperinsulinemia in alzheimer's disease , 1996, Neurobiology of Aging.

[60]  W. Klein,et al.  Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. , 2009, CNS & neurological disorders drug targets.

[61]  K. Kawahara,et al.  Primary Type 2 Microglia by Rat 42 - 1 -Amyloid Peptide b Oligomeric IL-4-Induced Selective Clearance of , 2008 .

[62]  Y. Zhong,et al.  PI3 kinase signaling is involved in Aβ-induced memory loss in Drosophila , 2010, Proceedings of the National Academy of Sciences.

[63]  I. Hakker,et al.  Aβ42 Mutants with Different Aggregation Profiles Induce Distinct Pathologies in Drosophila , 2008, PloS one.

[64]  S. Strittmatter,et al.  Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.

[65]  S. Craft,et al.  The Role of Insulin Resistance in the Pathogenesis of Alzheimer’s Disease , 2003, CNS drugs.

[66]  M. Abbott,et al.  The Insulin Receptor Tyrosine Kinase Substrate p58/53 and the Insulin Receptor Are Components of CNS Synapses , 1999, The Journal of Neuroscience.

[67]  N. Chattipakorn,et al.  Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. , 2011, Life sciences.

[68]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[69]  Sanjay Asthana,et al.  Insulin Metabolism in Alzheimer’s Disease Differs According to Apolipoprotein E Genotype and Gender , 1999, Neuroendocrinology.

[70]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[71]  Julie Harris,et al.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.

[72]  J. D. McGaugh,et al.  Inhibition of Activity-Dependent Arc Protein Expression in the Rat Hippocampus Impairs the Maintenance of Long-Term Potentiation and the Consolidation of Long-Term Memory , 2000, The Journal of Neuroscience.

[73]  J. Unger,et al.  Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications. , 1998, Histology and histopathology.

[74]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[75]  M. Beal,et al.  An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[76]  W. Klein,et al.  Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[77]  K. Zahs,et al.  Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.

[78]  H. Allain,et al.  Treatment of the mild cognitive impairment (MCI) , 2007, Human psychopharmacology.

[79]  Geeta S. Paranjape,et al.  Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line. , 2009, Biochemistry.

[80]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[81]  M. Szyf,et al.  A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.

[82]  Heike Wulff,et al.  Amyloid-β Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity* , 2010, The Journal of Biological Chemistry.

[83]  T. Tokuda,et al.  High-molecular weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients , 2010, Alzheimer's & Dementia.

[84]  D. Porte,et al.  Localization of insulin receptor mRNA in rat brain by in situ hybridization. , 1990, Endocrinology.

[85]  H. Ulrich,et al.  Peptide Blockers of the Inhibition of Neuronal Nicotinic Acetylcholine Receptors by Amyloid β* , 2005, Journal of Biological Chemistry.

[86]  Patrick R Hof,et al.  Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[88]  E. Rojas,et al.  Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[89]  H. Lin,et al.  Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  W Blaine Stine,et al.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.

[91]  Adriana B Ferreira,et al.  β-Amyloid-induced Dynamin 1 Degradation Is Mediated by N-Methyl-D-Aspartate Receptors in Hippocampal Neurons* , 2006, Journal of Biological Chemistry.

[92]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Brownstein,et al.  Insulin and insulin receptors in rodent brain. , 1981, Diabetologia.

[94]  A. Ott Risk of dementia: The Rotterdam Study , 1997 .

[95]  S. Ferreira,et al.  Soluble Protein Oligomers as Emerging Toxins in Alzheimer′s and Other Amyloid Diseases , 2007 .

[96]  R. Trullas,et al.  Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. , 2010, Cell calcium.

[97]  J. Born,et al.  Improving Influence of Insulin on Cognitive Functions in Humans , 2001, Neuroendocrinology.

[98]  L. Mucke,et al.  Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[99]  K. Kawahara,et al.  IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia1 , 2008, The Journal of Immunology.

[100]  G. Wilcock,et al.  Hyperinsulinaemia and Alzheimer's disease. , 1994, Age and ageing.

[101]  A. Draguhn,et al.  Amyloid β Oligomers (Aβ1–42 Globulomer) Suppress Spontaneous Synaptic Activity by Inhibition of P/Q-Type Calcium Currents , 2008, The Journal of Neuroscience.

[102]  E. Sigurdsson,et al.  Murine models of Alzheimer's disease and their use in developing immunotherapies. , 2010, Biochimica et biophysica acta.

[103]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[104]  N. Arispe Architecture of the Alzheimer's A beta P ion channel pore. , 2004, The Journal of membrane biology.

[105]  O. Arancio,et al.  Phospholipase D2 Ablation Ameliorates Alzheimer's Disease-Linked Synaptic Dysfunction and Cognitive Deficits , 2010, The Journal of Neuroscience.

[106]  C. Cotman,et al.  Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. , 1991, European journal of pharmacology.

[107]  J. Luchsinger Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. , 2008, European journal of pharmacology.

[108]  B. Kriem,et al.  Microtubule-associated Protein MAP1A, MAP1B, and MAP2 Proteolysis during Soluble Amyloid β-Peptide-induced Neuronal Apoptosis , 2006, Journal of Biological Chemistry.

[109]  C. Kahn,et al.  Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene , 1994, Nature.

[110]  S. Deadwyler,et al.  Experience-Dependent Regulation of the Immediate-Early Gene Arc Differs across Brain Regions , 2003, The Journal of Neuroscience.

[111]  T. Wyss-Coray,et al.  The p75 Neurotrophin Receptor Promotes Amyloid-β(1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo , 2009, The Journal of Neuroscience.

[112]  D. Alkon,et al.  Insulin and the insulin receptor in experimental models of learning and memory. , 2004, European journal of pharmacology.

[113]  B. Hyman,et al.  Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[114]  Claudio Soto,et al.  Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. , 2006, Trends in biochemical sciences.

[115]  Xiongwei Zhu,et al.  Insulin is a two-edged knife on the brain. , 2009, Journal of Alzheimer's disease : JAD.

[116]  M. Gobbi,et al.  Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.

[117]  M. Brownstein,et al.  Insulin and insulin receptors in rodent brain , 1981, Diabetologia.

[118]  N. Arispe Architecture of the Alzheimer’s AβP Ion Channel Pore , 2003, The Journal of Membrane Biology.

[119]  M. Eckenhoff,et al.  Inhaled Anesthetic Enhancement of Amyloid-&bgr; Oligomerization and Cytotoxicity , 2004, Anesthesiology.

[120]  C. Bouras,et al.  Down patients: Extracellular preamyloid deposits precede neuritic degeneration and senile plaques , 1989, Neuroscience Letters.

[121]  N. Ferguson,et al.  Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils , 2010, The Journal of Neuroscience.

[122]  R. Panizzutti,et al.  Aβ oligomers induce glutamate release from hippocampal neurons. , 2011, Current Alzheimer research.

[123]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-beta. , 2005, Nature neuroscience.

[124]  T. W. Smith,et al.  Optic nerve damage in shaken baby syndrome: detection by beta-amyloid precursor protein immunohistochemistry. , 2000, Archives of pathology & laboratory medicine.

[125]  C. Cotman,et al.  In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. , 1991, Brain research.

[126]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[127]  W. B. Stine,et al.  Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. , 1995, Experimental neurology.

[128]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[129]  E. Leznik,et al.  Microglial Receptor for Advanced Glycation End Product-Dependent Signal Pathway Drives β-Amyloid-Induced Synaptic Depression and Long-Term Depression Impairment in Entorhinal Cortex , 2010, The Journal of Neuroscience.

[130]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[131]  S. Ferreira,et al.  Amyloid-β Peptide Oligomers Disrupt Axonal Transport through an NMDA Receptor-Dependent Mechanism That Is Mediated by Glycogen Synthase Kinase 3β in Primary Cultured Hippocampal Neurons , 2010, The Journal of Neuroscience.

[132]  S. Kanba,et al.  Insulin resistance is associated with the pathology of Alzheimer disease , 2010, Neurology.

[133]  T. Montine,et al.  PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42 , 2006, Journal of neurochemistry.

[134]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[135]  C. Herron,et al.  Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. , 2001, Journal of neurophysiology.

[136]  W. K. Cullen,et al.  Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization , 2008, The Journal of Neuroscience.

[137]  S. M. de la Monte,et al.  Insulin resistance and Alzheimer's disease. , 2009, BMB reports.

[138]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[139]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[140]  C. Cotman,et al.  β-Amyloid impairs axonal BDNF retrograde trafficking , 2011, Neurobiology of Aging.

[141]  P. Mehta,et al.  Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.

[142]  K. Lee,et al.  Prion protein: orchestrating neurotrophic activities. , 2010, Current issues in molecular biology.

[143]  W. Klein,et al.  Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo , 2011, Journal of neuroscience research.

[144]  I. Weiler,et al.  Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome , 2008, Proceedings of the National Academy of Sciences.

[145]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[146]  G. Taglialatela,et al.  Amyloid‐β oligomers impair fear conditioned memory in a calcineurin‐dependent fashion in mice , 2010, Journal of neuroscience research.

[147]  L. Frölich,et al.  A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease , 1999, Annals of the New York Academy of Sciences.

[148]  David M Holtzman,et al.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. , 2005, Neuron.

[149]  R. Lal,et al.  Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .

[150]  W. K. Cullen,et al.  Block of LTP in rat hippocampus in vivo by β‐amyloid precursor protein fragments , 1997 .

[151]  N. Inestrosa,et al.  Wnt-5a occludes Aβ oligomer-induced depression of glutamatergic transmission in hippocampal neurons , 2010, Molecular Neurodegeneration.

[152]  Ronald D. Vale,et al.  Single-Molecule Microscopy Reveals Plasma Membrane Microdomains Created by Protein-Protein Networks that Exclude or Trap Signaling Molecules in T Cells , 2005, Cell.

[153]  W. Klein,et al.  Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.

[154]  C. Finch,et al.  Purification and characterization of brain clusterin. , 1994, Biochemical and biophysical research communications.

[155]  I. Sponne,et al.  Apoptotic Neuronal Cell Death Induced by the Non-fibrillar Amyloid-β Peptide Proceeds through an Early Reactive Oxygen Species-dependent Cytoskeleton Perturbation* , 2003, The Journal of Biological Chemistry.

[156]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[157]  C. Mirkin,et al.  Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[158]  J. Busciglio,et al.  Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta , 2009, Proceedings of the National Academy of Sciences.

[159]  L. Frölich,et al.  Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. , 2009, Journal of Alzheimer's disease : JAD.

[160]  W. Klein,et al.  Amyloid beta oligomers induce impairment of neuronal insulin receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[161]  Y. Christen,et al.  Amyloid-β-Induced Pathological Behaviors Are Suppressed by Ginkgo biloba Extract EGb 761 and Ginkgolides in Transgenic Caenorhabditis elegans , 2006, The Journal of Neuroscience.

[162]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[163]  L. Juliano,et al.  Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling* , 2008, Journal of Biological Chemistry.

[164]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[165]  M. Ehlers,et al.  Syntaxin-4 Defines a Domain for Activity-Dependent Exocytosis in Dendritic Spines , 2010, Cell.

[166]  A. Gonzalo-Ruiz,et al.  Soluble oligomeric forms of beta-amyloid (Aβ) peptide stimulate Aβ production via astrogliosis in the rat brain , 2010, Experimental Neurology.

[167]  H. Schoemaker,et al.  Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies , 2010, The Journal of Neuroscience.

[168]  C. Bonde,et al.  The metabotropic glutamate receptor agonist 1S,3R-ACPD stimulates and modulates NMDA receptor mediated excitotoxicity in organotypic hippocampal slice cultures , 2001, Brain Research.

[169]  C. Bagni On BC1 RNA and the fragile X mental retardation protein , 2008, Proceedings of the National Academy of Sciences.

[170]  O. Vitolo,et al.  Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[171]  Rie Teraoka,et al.  A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.

[172]  Fabiana A. Caetano,et al.  Amyloid‐beta oligomers increase the localization of prion protein at the cell surface , 2011, Journal of neurochemistry.

[173]  D. Porte,et al.  Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats , 1990, Peptides.

[174]  W. K. Cullen,et al.  Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. , 1997, Neuroreport.

[175]  D. Selkoe,et al.  Small non-fibrillar assemblies of amyloid β-protein bearing the Arctic mutation induce rapid neuritic degeneration , 2005, Neurobiology of Disease.

[176]  H. Wiśniewski,et al.  Non‐Fibrillar β‐Amyloid Protein is Associated with Smooth Muscle Cells of Vessel Walls in Alzheimer Disease , 1994, Journal of neuropathology and experimental neurology.

[177]  Lei Chang,et al.  Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening , 2007, Journal of Molecular Neuroscience.

[178]  R. V. Van Duyne,et al.  Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. , 2005, Journal of the American Chemical Society.

[179]  R. Lal,et al.  Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[180]  W. A. Pedersen,et al.  Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease , 2004, Neurobiology of Disease.

[181]  J. Wands,et al.  Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.

[182]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[183]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[184]  F. Nicoletti,et al.  β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.

[185]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[186]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[187]  Hollis T. Cline,et al.  Insulin Receptor Signaling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In Vivo , 2008, Neuron.

[188]  J. J. Dougherty,et al.  β-Amyloid Regulation of Presynaptic Nicotinic Receptors in Rat Hippocampus and Neocortex , 2003, The Journal of Neuroscience.

[189]  Shaomin Li,et al.  Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.

[190]  F. Sun,et al.  Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of β-secretase activation and β-amyloid generation in rat brains , 2009, Neuroscience.

[191]  D. Butterfield,et al.  Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. , 2001, Current medicinal chemistry.

[192]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[193]  James J. Hickman,et al.  A New Target for Amyloid Beta Toxicity Validated by Standard and High-Throughput Electrophysiology , 2010, PloS one.

[194]  R. Martins,et al.  Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner , 1999, Neuroscience.

[195]  K. Jellinger,et al.  Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.

[196]  D. Graham,et al.  A Neprilysin Polymorphism and Amyloid-β Plaques after Traumatic Brain Injury , 2009 .

[197]  G. D. Stewart,et al.  Genetic linkage map of human chromosome 21. , 1988, Genomics.

[198]  C. Carlsson,et al.  Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[199]  E. Rojas,et al.  Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[200]  L. Partridge,et al.  Insulin/IGF-like signalling, the central nervous system and aging. , 2009, The Biochemical journal.

[201]  E. Mufson,et al.  Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease , 2009, The Journal of Neuroscience.

[202]  S. Ferreira,et al.  Formation of Soluble Oligomers and Amyloid Fibrils with Physical Properties of the Scrapie Isoform of the Prion Protein from the C-terminal Domain of Recombinant Murine Prion Protein mPrP-(121–231)* , 2006, Journal of Biological Chemistry.

[203]  M. Rowan,et al.  Alzheimer's Disease Brain-Derived Amyloid-β-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein , 2011, The Journal of Neuroscience.

[204]  D. Selkoe Amyloid β protein precursor and the pathogenesis of Alzheimer's disease , 1989, Cell.

[205]  C. Finch,et al.  Self-assembly of Aβ1-42 into globular neurotoxins , 2003 .

[206]  M. Michikawa,et al.  Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. , 2009, The American journal of pathology.

[207]  S. Ferreira,et al.  Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts , 2007, Progress in Neurobiology.

[208]  P. Greengard,et al.  Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. , 2002, The American journal of pathology.

[209]  F. Baas,et al.  Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. , 2007, Antioxidants & redox signaling.

[210]  T. Kihara,et al.  Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. , 2006, Biochemical and biophysical research communications.

[211]  R. Vassar,et al.  The Role of Amyloid Precursor Protein Processing by BACE1, the β-Secretase, in Alzheimer Disease Pathophysiology* , 2008, Journal of Biological Chemistry.

[212]  T. Nabeshima,et al.  Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse , 2011, Molecular Neurodegeneration.

[213]  M. Kirkitadze,et al.  Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[214]  D. Graham,et al.  A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury. , 2009, Journal of neurotrauma.

[215]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[216]  D. Holtzman,et al.  Acute stress increases interstitial fluid amyloid-β via corticotropin-releasing factor and neuronal activity , 2007, Proceedings of the National Academy of Sciences.

[217]  N. Inestrosa,et al.  Role of the Wnt receptor Frizzled-1 in presynaptic differentiation and function , 2009, Neural Development.

[218]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[219]  C. Hetz,et al.  Amyloid β-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF. , 2011, Antioxidants & redox signaling.

[220]  A. Palmeri,et al.  Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.

[221]  M. Rowan,et al.  The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.

[222]  D. Selkoe,et al.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.

[223]  Ashley I. Bush,et al.  Therapeutics for Alzheimer’s disease based on the metal hypothesis , 2008, Neurotherapeutics.

[224]  J. Wands,et al.  Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[225]  Rosemary O’Connor,et al.  Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.

[226]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[227]  R. Tanzi,et al.  The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.

[228]  J. De Keyser,et al.  D1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease. , 1990, Archives of neurology.

[229]  W. Klein,et al.  Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. , 2009, Toxicology and applied pharmacology.

[230]  D. Selkoe,et al.  Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.

[231]  R. Malinow,et al.  The prion protein as a receptor for amyloid-β , 2010, Nature.

[232]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[233]  W. Engel,et al.  Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers , 2010, Acta Neuropathologica.

[234]  P. Livrea,et al.  Soluble β-Amyloid1-40 Induces NMDA-Dependent Degradation of Postsynaptic Density-95 at Glutamatergic Synapses , 2005, The Journal of Neuroscience.

[235]  F. LaFerla,et al.  Aβ inhibits the proteasome and enhances amyloid and tau accumulation , 2008, Neurobiology of Aging.

[236]  O. Forlenza,et al.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease , 2008, Psychopharmacology.

[237]  Carl W. Cotman,et al.  In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.

[238]  G. Glenner,et al.  Immunohistochemical evidence for the derivation of a peptide ligand from the amyloid beta-protein precursor of Alzheimer disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[239]  W. Klein,et al.  Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria , 2010, PloS one.

[240]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[241]  A. Michelucci,et al.  Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-β , 2009, Journal of Neuroimmunology.

[242]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[243]  T. Morgan,et al.  Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.

[244]  K. Hsu,et al.  Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation , 2009, Neurobiology of Aging.

[245]  S. Woods,et al.  Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. , 2000, Diabetes.

[246]  W. Klein Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer’s Disease as a Case Study , 2006 .

[247]  A. García-Osta,et al.  Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology , 2010, Neuropsychopharmacology.

[248]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[249]  W. Klein,et al.  Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* , 2009, The Journal of Biological Chemistry.

[250]  G. Schellenberg,et al.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.

[251]  R. Hepler,et al.  Solution state characterization of amyloid beta-derived diffusible ligands. , 2006, Biochemistry.

[252]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[253]  D. Alkon,et al.  Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.

[254]  J. Wands,et al.  Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.

[255]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[256]  J. Marx Fresh Evidence Points to an Old Suspect: Calcium , 2007, Science.

[257]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[258]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[259]  Kristen M Harris,et al.  Dendritic Spine Pathology: Cause or Consequence of Neurological Disorders? , 2002, Brain Research Reviews.

[260]  K. Hsu,et al.  Insulin Stimulates Postsynaptic Density-95 Protein Translation via the Phosphoinositide 3-Kinase-Akt-Mammalian Target of Rapamycin Signaling Pathway* , 2005, Journal of Biological Chemistry.

[261]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.

[262]  Xiaohua Douglas Zhang,et al.  Inhibition of Calcineurin-mediated Endocytosis and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid β Oligomer-induced Synaptic Disruption , 2009, The Journal of Biological Chemistry.

[263]  O. Vitolo,et al.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. , 2004, The Journal of clinical investigation.

[264]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[265]  S. Nicolaidis,et al.  Basal and hyperinsulinemia-induced immunoreactive hypothalamic insulin changes in lean and genetically obese Zucker rats revealed by microdialysis , 1993, Brain Research.

[266]  B. Kriem,et al.  Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of the amyloid‐β peptide , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[267]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[268]  B. Oostra,et al.  The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses , 2003, Cell.

[269]  M. Lambert,et al.  Intraneuronal amyloid-beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo , 2011, Alzheimer's & Dementia.

[270]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[271]  H. Vinters,et al.  β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.

[272]  Shao-Jun Tang,et al.  Activity-dependent Synaptic Wnt Release Regulates Hippocampal Long Term Potentiation* , 2006, Journal of Biological Chemistry.

[273]  D. Diamond,et al.  Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes , 2001, Brain Research.

[274]  W. Klein,et al.  N‐Methyl‐d‐aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid‐β peptide oligomers , 2010, Journal of neurochemistry.

[275]  J. Wands,et al.  Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[276]  K. Herrup,et al.  Aβ Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's Disease , 2008, The Journal of Neuroscience.

[277]  I. Izquierdo,et al.  Physiology of the prion protein. , 2008, Physiological reviews.

[278]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[279]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[280]  Brett Chromy,et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.

[281]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[282]  W. Klein,et al.  Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.

[283]  M. Reger,et al.  Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.

[284]  K. Reymann,et al.  Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors , 2011, Neurobiology of Aging.

[285]  C. Finch,et al.  Self-assembly of Abeta(1-42) into globular neurotoxins. , 2003, Biochemistry.

[286]  D. Selkoe,et al.  Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. , 1987, Science.

[287]  C. Robinson,et al.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. , 2009, Nature chemistry.

[288]  Jens C. Brüning,et al.  The role of insulin receptor signaling in the brain , 2005, Trends in Endocrinology & Metabolism.